Investment Thesis
Ligand demonstrates strong fundamental health with 60.4% revenue growth, fortress-like balance sheet (0.03x D/E ratio), and positive free cash flow generation. However, net income growth appears driven by non-operating items rather than core business expansion, creating sustainability concerns around reported profitability.
Strengths
- Strong revenue growth of 60.4% YoY demonstrates market demand and business expansion
- Fortress balance sheet with minimal debt (27.5M), exceptional liquidity (22.23x current ratio), and 174.9M in cash
- Positive operating cash flow (49.4M) and free cash flow (48.9M) indicate underlying business generates real cash
- Very low leverage (0.03x D/E) provides financial flexibility for growth investments or shareholder returns
Risks
- Net income growth of 3186.6% appears inflated by non-operating items; operating income only 33% of net income signals one-time gains or unusual items unlikely to repeat
- Disconnect between operating margin (15.3%) and net margin (46.4%) indicates sustainability risk in reported profitability
- Pharmaceutical sector subject to regulatory, clinical trial, and intellectual property risks; high insider activity (16 Form 4s in 90 days) may indicate profit-taking
- Sustainability of 60.4% revenue growth uncertain; high current ratio (22.23x) suggests potential capital inefficiency or defensive cash positioning
Key Metrics to Watch
- Organic revenue growth trends and mix of licensing/non-operating income vs core product revenue
- Operating income and operating margin sustainability to validate net income quality
- Operating cash flow consistency and FCF conversion rate to confirm cash generation capability
Financial Metrics
Revenue
268.1M
Net Income
124.5M
EPS (Diluted)
$6.13
Free Cash Flow
48.9M
Total Assets
1.6B
Cash
174.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
15.3%
Net Margin
46.4%
ROE
12.2%
ROA
8.0%
FCF Margin
18.2%
Balance Sheet & Liquidity
Current Ratio
22.23x
Quick Ratio
21.98x
Debt/Equity
0.03x
Debt/Assets
34.8%
Interest Coverage
290.79x
Long-term Debt
27.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T13:57:25.696418 |
Data as of: 2025-12-31 |
Powered by Claude AI